SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to strong community support and ongoing building efforts, including IRL initiatives and new product teases like KENDU SPICE. Community members express conviction and encourage others to join the movement, emphasizing KENDU's potential to become a major brand. Discussions also highlight the upcoming KENDU Games release and various merchandise offerings.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending due to recent earnings, where revenue increased, and full-year outlook was raised, despite a mixed market reaction. The community is debating whether the current price reflects the company's long-term potential in the AI space, with discussions around profitability targets and potential market manipulation. Bullish sentiment remains as some highlight strong fundamentals, recent analyst upgrades, and future growth catalysts, while others express concern over the stock's performance relative to its sector.

Monero

Monero is gaining traction as community members emphasize its importance as a leading privacy coin, drawing comparisons to what Bitcoin was originally intended to be. Despite some exchanges delisting XMR, discussions highlight Monero's solid use case, adoption in certain markets, and potential for significant growth as privacy becomes more valued in the crypto space. The community believes Monero is undervalued and poised for a substantial move.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential acquisition, especially after Pfizer's recent move in the obesity market, sparking discussions about Viking's value and potential suitors. Community members are debating the company's valuation, comparing its assets to competitors, and analyzing potential buyout scenarios. Discussions also include the impact of potential Medicare/Medicaid coverage on the obesity market and potential partnership.

Dogelon Mars

Dogelon Mars is trending amidst mixed community sentiment, with some expressing frustration over price movement and unrealized gains, while others remain hopeful and accumulate more tokens. The community is closely watching for potential catalysts like a significant burn or metaverse integration, but some express concern over broken promises from the development team. General market volatility and influence from broader crypto trends are also being discussed.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid reports of a potential breakup into two separate companies, focusing on sauces and condiments versus grocery products, which has sparked discussion about unlocking shareholder value. While some are skeptical, pointing to existing debt and margin concerns, others see an opportunity for strategic focus and growth, especially with the high dividend yield becoming more attractive amidst potential rate cuts. Community members are actively debating whether this split will truly benefit the stock or if it's simply rearranging a struggling business.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending amidst speculation surrounding the extension of ACA subsidies and the potential impact on the company's future profitability, further fueled by mixed earnings reports in the healthcare sector. The stock exhibits high volatility, with community members debating whether to buy, sell, or hold, based on their outlook for ACA and the company's 2026 profitability guidance. Some traders are closely watching technical indicators for potential entry or exit points, while others are highlighting large institutional ownership as a bullish sign.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending amid discussions around potential ACA subsidy extensions and the impact of a possible government shutdown on healthcare. Community members are weighing the implications of Trump's comments on healthcare and potential impacts on insurance companies, while also considering Centene's financial outlook and potential for growth in the sector.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as investors compare it to PLTR and IREN, anticipating a similar breakout. The company's recent collaboration and supply agreements are fueling optimism, with community members citing a large commercial pipeline. Discussions revolve around key resistance levels and potential for significant growth in the energy storage sector, particularly related to AI and hyperscalers.

Endeavour Silver Corp. is a mineral company, which engages in the evaluation, acquisition, development and exploitation of precious metal properties in Mexico and Chile. The firm's projects include the Terronera property in Jalisco, the El Compas property, the Guanacevi Mine in Durango, Bolanitos Mines in Guanajuato, and the Parral project in Chihuahua, Mexico. The company was founded by Bradford James Cooke on March 11, 1981 and is headquartered in Vancouver, Canada.

Endeavour Silver Corp.

Endeavour Silver ($EXK) is trending due to discussions around the Terronera mine's progress toward commercial production and the impact on future earnings. Community members are analyzing recent production numbers and potential catalysts, while also debating the effects of short selling and potential manipulation on the stock's price. The broader context involves rising silver prices and the company's expansion efforts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our...

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results.
read more...

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
read more...

12 titoli sanitari in movimento, after-market del 22/03/2024

Titoli in rialzo
Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd .
Il titolo Masimo (NASDAQ:MASI) ha osservato...

12 acciones de salud en movimiento en la subasta de cierre del 22/03/2024

Acciones al alza
Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes.
Masimo (NASDAQ:MASI...

Salarius Pharmaceuticals GAAP EPS of -$3.84

Salarius Pharmaceuticals GAAP EPS of -$3.84...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from...

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Salarius Pharmaceuticals Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc